William Blair & Company
VNRX icon

William Blair & Company’s VolitionRx Ltd VNRX Stock Holding History

William Blair & Company’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$30.4K – 1913
2025
Q2 		$30.4K Buy
+2,000
New +$22K ﹤0.01% 1652

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's VNRX Position: Q3 2025 in Review

William Blair & Company sold out of VolitionRx Ltd (VNRX) in Q3 2025, closing a stake of 2,000 shares — an estimated $30.4K sold.

William Blair & Company first reported a position in VNRX in Q2 2025 and held it in 1 quarter. The position peaked at $30.4K in Q2 2025. 33 funds tracked by Wall St. Rank hold VNRX as of Q3 2025.

  • William Blair & Company reported no remaining VolitionRx Ltd position as of Q3 2025 after selling out during the quarter.
  • William Blair & Company sold 2,000 VolitionRx Ltd shares in Q3 2025, an estimated $30.4K.
  • William Blair & Company first reported a position in VolitionRx Ltd in Q2 2025 and held it in 1 quarter.
  • William Blair & Company's VolitionRx Ltd position peaked at $30.4K in Q2 2025.
  • 33 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q3 2025.

Based on William Blair & Company's 13F filing for Q3 2025, filed 12 Nov 2025.